Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646 1674
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18528157 | ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17621303 | IN SITU RECRUITMENT, REPROGRAMMING, AND RELEASE OF CAR-T CELLS | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 17868305 | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | Non-Final OA | NOVARTIS AG |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | Non-Final OA | Novartis AG |
| 18627727 | COMBINED ADMINISTRATION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy